Gary Edd Fish, MD
Areas of Focus | Medical Retina
Office Locations | Dallas Main, Arlington, Plano, Rockwall, Wichita Falls
Certification | American Board of Ophthalmology
Languages Spoken | English
Fellowship
Surgical Retina Diseases
Texas Retina Associates
Dallas, Texas
Ocular Echography
University of Iowa
Iowa City, Iowa
Medical Retinal Diseases
Moorsfields Eye Hospital
London, England
Residency
Ophthalmology
University of Texas Southwestern Medical School
Dallas, Texas
Internship
New York Veterans Administration Hospital
Bellevue Hospital
New York, New York
Medical School
University of Texas Southwestern Medical School
Dallas, Texas
- American Academy of Ophthalmology
- American Ophthalmological Society
- American Society of Retina Specialists
- American Uveitis Society
- Dallas Academy of Ophthalmology
- Dallas County Medical Society
- The Macula Society
- The Retina Society
- Texas Medical Association
- Texas Ophthalmological Association
- Principal Investigator: OPH1004B Study – Phase 3, Double-Masked, Control Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™(anti PDGF-B Pegylated Aptamer) Administered in Comination with either Avastin® or Eylea® or Eylea® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration.
- Principal Investigator: OPH1003 Study – Treatment for Subfoveal Choroidal Neovascularation secondary to AMD, Sponsored by Ophthotech Corp.
- Principal Investigator: LT1009-Oph-003 Lpath Study –Treatment for Wet AMD, Sponsored by Lpath, Inc.
- Principal Investigator: Comparison of AMD Treatments Trials (CATT) Follow-up Study (CATT FS), Sponsored by the National Eye Institute
- Sub-Investigator: EYEGUARD Study-Treatment for Uveitis, Sponsored by XOMA
- Principal Investigator: AREDS2 Sirolimus-Treatment for GA, Sponsored by National Eye Institute
- Sub-Investigator: Protocol GX28198 OLEi, Sponsored by Genentech
- Sub-Investigator: Protocol TG-MV-014 – Oasis, Sponsored by ThromboGenics
- Sub-Investigator: Protocol CFD4870g Mahalo, Sponsored by Genentech
- Sub-Investigator: Protocol LX211-11, Sponsored by LUX Biosciences, Inc.
- Sub-Investigator: Protocol M10-877; M10-880; M11-327, Sponsored by Abbott Laboratories
- Sub-Investigator: Protocol PJMR0092103, Sponsored by Novartis Pharmaceuticals
- Sub-Investigator: Alcon C-08-36; Geographic Atrophy Treatment Evaluation (GATE), Sponsored by Alcon
- Sub-Investigator: Protocol 4429-201, Sponsored by Acucela Inc.
- Principal Investigator: CoMentis ATG003-203 Study, Sponsored by Comentis, Inc. (completed)
- Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A Randomized, Placebo-controlled Clinical Trial of Docosahexaenoic Acid Supplementation for X-linked Retinitis Pigmentosa. American Journal of Ophthalmology 137(4):704-18, Apr 2004. https://www.ncbi.nlm.nih.gov/pubmed/15059710?dopt=Abstract
- Potter MJ, Reaves A, Rosenfeld PJ, Sickenberg M, Slakter JS, Soubrane G, Strong HA, Stur M; Acute Sever Visual Acuity Decrease after Photodynamic Therapy with Verteporfin: Case Reports from Randomized Clinical Trials – TAP and VIP report no. 3. American Journal of Ophthalmology 137(4):683-96, Apr 2004.
- Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group, Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, Fish GE, Hao Y, Haynes L, Lim JI, Menchini U, Miller JW, Mones J, Potter MJ, Reaves A, Rosenfeld PJ, Strong A, Su XY, Slakter JS, Schmidt-Erfurth U, Sorenson JA; Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Meta-analysis of 2-year Safety Results in Three Randomized Clinical Trials: Treatment Of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 24(1):1-12, Feb 2004.
- Eyetech Study Group, Anti-vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Phase II Study Results. Ophthalmology 110(5): 979-986, May 2003.
- Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Group, Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donato G, Hao Y, Ma C, Menchini U, Miller JW, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Strong HA, Stur M, Su XY; Effect of Lesion Size, Visual Acuity, and Lesions Composition on Visual Acuity Change With and Without Verteporfin Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: TAP and VIP Report #1. American Journal of Ophthalmology 136(3):407-418, Sept 2003.
- Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group and Verteporfin in Photodynamic Therapy (VIP) Study Group, Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wendenstern A; Photodynamic Therapy of Subfoveal Choroidal Neovascularization with Verteporfin: Fluorescein Angiographic Guidelines for Evaluation and Treatment – TAP and VIP Report #2. Archives of Ophthalmology 121(9):1253-1268: Sept 2003.
- Verteporfin in Photodynamic Therapy (VIP) Study Group, Blinder KJ, Blumendranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LF, Slakter JS, Strong HA, Virgili G, Williams GA; Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia: 2-year Results of a Randomized Clinical Trial – VIP Report #3. Ophthalmology 110(4):667-673, Apr 2003.
- Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Patients with Age-Related Macular Degeneration: Additional Information Regarding Baselines Lesion Composition’s Impact on Vision Outcomes – TAP Report #3. Archives of Ophthalmology 120(11):1143-1454, Nov 2002.
- Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Verteporfin Therapy for Subfoveal Neovascularization in Age-Related Macular Degeneration: Three-Year Results of An Open-Label Extension of 2 Randomized Clinical Trials – TAP Report #5. Archives of Ophthalmology 120(10):1307-1314, Oct 2002.
- Birch DG, Toler SM, Swanson WH, Fish GE, Laties AM. A Double-blind Placebo-controlled Evaluation of the Acute Effects of Sildenafil Citrate (Viagra) on Visual Function in Subjects with Early-stage Age-related Macular Degeneration. American Journal of Ophthalmology 133(5):665-72, May 2002. https://www.ncbi.nlm.nih.gov/pubmed/11992864?dopt=Abstract
- American Academy of Ophthalmology Honor Award